T. Rowe Price’s target-date series will change its equity glide path and add two underlying funds. The comprehensive, two-year research process behind the changes illustrates the extent of the firm’s multi-asset capabilities. The series retains a Morningstar Analyst Rating of Silver for its cheapest share classes. The more expensive classes range from Bronze to Neutral.
T. Rowe Price Retirement 2020 TRRBX
NAV / 1-Day Return
22.80
/
0.31
%
Total Assets
15.7 Bil
Adj. Expense Ratio
Adjusted Expense Ratio excludes certain variable investment-related expenses, such as interest from borrowings and dividends on borrowed securities, allowing for more consistent cost comparisons across funds.
0.580%
Expense Ratio
0.580%
Fee Level
Average
Longest Manager Tenure
18.00
years
Category
US Fund Target-Date 2020
Investment Style
Large BlendCredit Quality / Interest Rate Sensitivity
Low / ModerateStatus
Open
TTM Yield
2.04%
Turnover
19%
Premium
Morningstar’s Analysis
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
Will TRRBX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
Process Pillar
The Process Pillar is our assessment of how sensible, clearly defined, and repeatable TRRBX’s performance objective and investment process is for both security selection and portfolio construction.
People Pillar
The People Pillar is our evaluation of the TRRBX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of TRRBX’s parent organization’s priorities and whether they’re in line with investors’ interests.
Updates to this target-date series highlight T. Rowe Price's research might.
